Literature DB >> 25114875

Development and application of a novel sensitive immunometric assay for calcitonin in a large cohort of patients with medullary and differentiated thyroid cancer, thyroid nodules, and autoimmune thyroid diseases.

Cléber P Camacho1, Susan C Lindsey1, Teresa S Kasamatsu1, Alberto L Machado2, João Roberto M Martins1, Rosa Paula M Biscolla2, Magnus R Dias da Silva1, José Gilberto H Vieira2, Rui M B Maciel2.   

Abstract

BACKGROUND: Serum calcitonin (sCT) is a useful biomarker for medullary thyroid cancer (MTC). Consensus has not been reached concerning sCT measurements in the evaluation of nodular thyroid disease (NTD). OBJECTIVE AND METHODS: We developed a new immunofluorometric assay for sCT and have validated it in samples from 794 patients [203 with MTC, 205 with autoimmune thyroid disease (ATD), 248 with NTD, 80 with differentiated thyroid cancer (DTC) 'free of disease', 58 with chronic renal failure (CRF)] and 178 normal individuals, including samples after pentagastrin tests and samples from the washout of 92 FNA procedures in patients with NTD or MTC. We also compared some samples from patients with low or high calcitonin levels using both this assay and the Nichols Institute Diagnostics (NID) assay.
RESULTS: The assay's analytical sensitivity was 1.0 pg/ml. Considering MTC patients prior to surgery, the cut-off values for the 95% reference range were 11.1 pg/ml for males and 5.5 pg/ml for females and employing the ROC curve were 18.4 pg/ml for males and 7.8 pg/ml for females. sCT in patients with MTC was strongly correlated with disease status. Patients with NTD and ATD did not present false-positive results. sCT measurements were significantly correlated with age (excluding MTC and CRF). The NID test had a strong correlation with our assay. A hook effect was observed only with concentrations >200,000 pg/ml.
CONCLUSIONS: We developed a novel sCT assay and validated it in healthy subjects, as well as in a large cohort of patients with MTC, NTD, ATD, DTC, and CRF.

Entities:  

Keywords:  Autoimmune thyroid disease; Calcitonin; Immunometric assay; Medullary thyroid carcinoma; Thyroid nodule

Year:  2014        PMID: 25114875      PMCID: PMC4109516          DOI: 10.1159/000363055

Source DB:  PubMed          Journal:  Eur Thyroid J        ISSN: 2235-0640


  35 in total

1.  Prevalence of heterophilic antibody interference in eight automated tumor marker immunoassays.

Authors:  Carol M Preissner; Larry A Dodge; Dennis J O'Kane; Ravinder J Singh; Stefan K G Grebe
Journal:  Clin Chem       Date:  2005-01       Impact factor: 8.327

2.  Measurement of calcitonin by immunoassay analyzers.

Authors:  Christian Bieglmayer; Heinrich Vierhapper; Robert Dudczak; Bruno Niederle
Journal:  Clin Chem Lab Med       Date:  2007       Impact factor: 3.694

3.  Construction and clinical validation of a sensitive and specific assay for serum mature calcitonin using monoclonal anti-peptide antibodies.

Authors:  P Motté; P Vauzelle; P Gardet; P Ghillani; B Caillou; C Parmentier; C Bohuon; D Bellet
Journal:  Clin Chim Acta       Date:  1988-05-13       Impact factor: 3.786

4.  "Hook effect" in calcitonin immunoradiometric assay in patients with metastatic medullary thyroid carcinoma: case report and review of the literature.

Authors:  Rébecca Leboeuf; Marie-France Langlois; Marc Martin; Charaf E Ahnadi; Guy D Fink
Journal:  J Clin Endocrinol Metab       Date:  2005-11-08       Impact factor: 5.958

5.  Abnormal calcitonin basal levels and pentagastrin response in patients with chronic renal failure on maintenance hemodialysis.

Authors:  P Niccoli; P Brunet; C Roubicek; F Roux; E Baudin; P J Lejeune; Y Berland; B Conte-Devolx
Journal:  Eur J Endocrinol       Date:  1995-01       Impact factor: 6.664

6.  Thyroid nodules and differentiated thyroid cancer: update on the Brazilian consensus.

Authors:  Pedro Weslley Rosário; Laura S Ward; Gisah A Carvalho; Hans Graf; Rui M B Maciel; Léa Maria Z Maciel; Ana Luiza Maia; Mário Vaisman
Journal:  Arq Bras Endocrinol Metabol       Date:  2013-06

7.  Basal and stimulated calcitonin and procalcitonin by various assays in patients with and without medullary thyroid cancer.

Authors:  Jürgen Kratzsch; Anne Petzold; Friedhelm Raue; Walter Reinhardt; Martina Bröcker-Preuss; Rainer Görges; Klaus Mann; Wolfram Karges; Nils Morgenthaler; Markus Luster; Christoph Reiners; Joachim Thiery; Henning Dralle; Dagmar Fuhrer
Journal:  Clin Chem       Date:  2010-12-15       Impact factor: 8.327

8.  Early diagnosis and curative therapy of medullary thyroid carcinoma by routine measurement of serum calcitonin in patients with thyroid disorders.

Authors:  H Vierhapper; B Niederle; C Bieglmayer; K Kaserer; S Baumgartner-Parzer
Journal:  Thyroid       Date:  2005-11       Impact factor: 6.568

9.  The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer.

Authors:  Herbert Chen; Rebecca S Sippel; M Sue O'Dorisio; Aaron I Vinik; Ricardo V Lloyd; Karel Pacak
Journal:  Pancreas       Date:  2010-08       Impact factor: 3.327

Review 10.  Systematic review of clinical practice guidelines in the diagnosis and management of thyroid nodules and cancer.

Authors:  Tsai-Wei Huang; Jun-Hung Lai; Mei-Yi Wu; Shiah-Lian Chen; Chih-Hsiung Wu; Ka-Wai Tam
Journal:  BMC Med       Date:  2013-08-29       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.